Predict your next investment

Hemex Health company logo
HEALTHCARE | Disease Diagnosis
hemexhealth.com

See what CB Insights has to offer

Stage

Unattributed VC | Alive

Total Raised

$6.29M

Last Raised

$200K | 5 mos ago

About Hemex Health

Hemex creates affordable, life-changing medical diagnostics for under-served people everywhere. Its diagnostic platform is designed to reach populations at risk for malaria and sickle cell disease.

Hemex Health Headquarter Location

4640 SW Macadam Ave Ste. 250

Portland, Oregon, 97239,

United States

503-703-7696

Latest Hemex Health News

Researchers from India’s National Institute of Research in Tribal Health Confirm Gazelle’s Ability to Accurately Diagnose Sickle Cell Disease in Remote Regions

Oct 13, 2021

Intellasia East Asia News Rapid, Low-Cost, Point-of Care Diagnostic Could Improve Patient Care and Save Lives in Hard to Test Areas MUMBAI, India & PORTLAND, Ore.--(BUSINESS WIRE)--Research published today in the journal Frontiers in Medicine found that Gazelle™, a diagnostic platform from Hemex Health, has 99% accuracy in diagnosing sickle cell disease (SCD). The research team, from India’s National Institute of Research in Tribal Health (NIRTH), have been hoping to find a low cost, highly accurate, point-of-care rapid detection test for SCD because current testing requires sending samples to a lab, resulting in delays, inability to communicate with patients, and in some cases corruption of the studies due to heat or rough conditions. “At least 15% of all newborns with sickle cell disease are from India, and it is estimated that 20% of Indian children with sickle cell disease die from related illnesses before reaching their second birthday,” said Dr. Shanmugam Rajasubramaniam, Head, Division of Genetic Disorders, ICMR-National Institute of Research in Tribal Health. “Early diagnosis could start these children on life-saving therapies, but only a few public health facilities for diagnosis of sickle cell disease and patient care exist. A device like Gazelle that can be taken to remote areas could expand patient care significantly and save many lives.” In the study, the NIRTH team tested Gazelle to compare its accuracy against the standard laboratory tests, HPLC and hemoglobin electrophoresis. The results showed Gazelle performing with similar accuracy, but with more speed and ease. The study included 960 subjects from the tribal states of Chhattisgarh and Madhya Pradesh, who ranged in age from 6 months to 65 years. Gazelle identified all patients with disease (HbSS) with 100% accuracy. Gazelle demonstrated 100% sensitivity when comparing sickle cell disease versus sickle cell trait and sickle cell disease versus normal. Gazelle exhibited high sensitivity and specificity for detection of each relevant hemoglobin phenotype (normal, carrier, and disease states). Overall, Gazelle yielded a high accuracy (99.0%) compared to the reference standard tests, hemoglobin electrophoresis and HPLC. “Hemex recognizes the critical need for at-risk populations to have access to affordable, accurate testing,” said Patti White, Co-founder and CEO, Hemex Health. “Clinicians in remote low resource locations told us what was needed, and we listened. Our sickle cell test uses a miniaturized version of electrophoresis – a technology widely known and trusted by clinicians – packaged in a portable, battery-powered device. We made it fast and easy-to-use with minimal training, and rugged enough for the hot and humid conditions that one often finds in the field.” Researchers noted many of Gazelle’s ease-of-use features that would be valuable in field settings, including error detection software that senses problems with sample preparation and the automated interpretation of each sample. The short test time (about 12 minutes from sample to result) allows a report to be generated during the visit, ensuring that treatment and education can begin immediately. Because the device stores patient results locally or can transmit them to the cloud or printer, clinicians can easily track the patient’s history. Please click to continue reading this release. Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Hemex Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Hemex Health is included in 4 Expert Collections, including Medical Devices.

M

Medical Devices

8,521 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

3,091 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

I

Infectious Disease

2,226 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

B

Biopharmaceuticals

5,880 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Hemex Health Patents

Hemex Health has filed 12 patents.

The 3 most popular patent topics include:

  • Blood tests
  • Medical tests
  • Liberal democracies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/25/2020

7/13/2021

Rare diseases, Transcription factors, Biotechnology, Syndromes, Digestive system

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/25/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

7/13/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Rare diseases, Transcription factors, Biotechnology, Syndromes, Digestive system

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Hemex Health Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Hemex Health Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.